Pivmecillinam Hydrochloride: Oral Mecillinam Prodrug for Acute Uncomplicated Cystitis

Pivmecillinam hydrochloride is the salt form of pivmecillinam, an orally available prodrug of mecillinam (amdinocillin). Mecillinam is a beta lactam antibiotic from the class of amidinopenicillins that is poorly absorbed when taken orally. The ester linkage with pivalinic acid created pivmecillinam, an orally active prodrug. In Germany, pivmecillinam hydrochloride is marketed under the trade name Pivmelam for the treatment of acute uncomplicated cystitis in women. In Scandinavian countries, it is more widespread under the name Selexid and has been standard therapy for decades.

Pivmecillinam was (re)approved in Germany in 2018, after being successfully used for decades in Scandinavian countries for uncomplicated urinary tract infections. The German S3 guideline for the treatment of uncomplicated urinary tract infections recommends pivmecillinam alongside fosfomycin and nitrofurantoin as first-line therapy, primarily because of proven efficacy and comparatively low resistance rates.

Mechanism of Action and Salt Form

Pivmecillinam is rapidly hydrolyzed in the intestine and liver by esterases to mecillinam and pivalinic acid. Mecillinam is a beta lactam antibiotic with selective high affinity for PBP2 in gram-negative bacteria. This specific PBP2 binding leads to spherical shape changes and lysis primarily of gram-negative pathogens such as Escherichia coli (major causative agent of uncomplicated UTI), Klebsiella pneumoniae, Proteus mirabilis, and certain other Enterobacterales.

The selective activity against gram-negative pathogens and high concentration in urine make mecillinam a first choice option for uncomplicated cystitis. Activity against gram-positive bacteria such as Staphylococcus saprophyticus (second most common UTI pathogen) is weaker. Resistance rates of E. coli to mecillinam are low in Europe at 2 to 8 percent, considerably better than with cotrimoxazole or fluoroquinolones.

Pharmacokinetically, pivmecillinam has oral bioavailability of approximately 65 percent. Mecillinam accumulates to high concentrations in urine (over 100 mg/L with normal renal function), which explains the antibacterial efficacy in the urinary tract. Half-life approximately 1 hour, which is why multiple daily doses are required.

Indications

• Acute uncomplicated cystitis in women: first-line therapy according to German S3 guideline 2017
• Acute uncomplicated pyelonephritis: with low severity and secure pathogen profile as an oral option
• Asymptomatic bacteriuria in pregnancy: after resistance testing as a safe option
• Prophylaxis of recurrent urinary tract infections: off-label, for frequent recurrences

Dosage and Administration

Acute cystitis: 400 mg three times daily for 3 days (short treatment duration is sufficient for uncomplicated cystitis and reduces selection pressure for resistance).

Pyelonephritis: 400 mg three times daily for 7 to 14 days, with inpatient treatment or as follow-up to parenteral therapy.

Administration: with adequate water, with or without food. Take while standing or sitting upright, as the tablet can cause esophageal irritation if taken while lying down and becomes lodged in the esophagus.

In renal impairment: with eGFR below 30 ml/min, possibly reduced efficacy due to lower urine concentration. Pregnancy: Pivmecillinam is considered safe and is an established option for UTI during pregnancy.

Adverse Effects

Common: generally well tolerated. Nausea, diarrhea, abdominal pain, rash, pruritus.

Occasional: vomiting, headache, vaginal candidiasis (from microbiome shifts), allergic reactions, elevated liver transaminases.

Rare but important: anaphylactic reactions (beta lactam allergy), severe skin reactions (Stevens Johnson syndrome), Clostridioides difficile associated diarrhea, hypoglycemia, and carnitine deficiency with prolonged therapy (from pivaloyl binding).

Important: with known beta lactam allergy, pivmecillinam is contraindicated due to possible cross-reactivity. Carnitine deficiency is a specific adverse effect of pivaloyl binding, clinically relevant only with very prolonged use or in high-risk patients (e.g., children with inherited metabolic disorders).

Drug Interactions

• Probenecid: prolongs half-life through inhibition of renal tubular secretion
• Other beta lactam antibiotics: do not prescribe together without indication
• Methotrexate: may reduce renal MTX clearance with high-dose therapy
• Hormonal contraceptives: theoretical reduction through microbiome changes, clinically of minor relevance
• Valproic acid: pivalinic acid binding to carnitine can lead to hyperammonemia, use caution

Special Precautions

Pregnancy: Pivmecillinam is considered safe and is an established option for acute cystitis and asymptomatic bacteriuria in pregnancy, especially in Scandinavian countries with long-standing experience. Breast-feeding: Use is possible, with minimal transfer to breast milk and no clinical relevance for the infant.

Before therapy: clinical diagnosis of cystitis is sufficient, urine culture is not mandatory for the uncomplicated form. For recurrent UTI or atypical presentation, urine culture and resistance testing are useful.

Carnitine deficiency: in high-risk patients (children, malnutrition, metabolic disorders), carnitine supplementation may be beneficial, especially with long-term use. With standard 3-day therapy, this is not relevant.

Antibiotic Stewardship: Pivmecillinam is an effective narrow-spectrum antibiotic with low selection pressure for resistance, making it the preferred first-line therapy from a stewardship perspective. Fluoroquinolones should be avoided when possible for uncomplicated cystitis.

You May Also Be Interested In

• Mecillinam, the active ingredient (Pillar Page)
• Fosfomycin, another first-line therapy for cystitis
• Nitrofurantoin, classic UTI therapy
• Cotrimoxazole, alternative UTI therapy (consider resistance patterns)
• Ciprofloxacin, fluoroquinolone with reserve indication

Frequently Asked Questions

Sources

• AWMF S3 Guideline Uncomplicated Urinary Tract Infections
• Gelbe Liste, Pivmecillinam Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• EMA Product Information for Pivmecillinam Products